LIOTHYRONINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H12I3NO4
Molecular Weight	650.9735
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C(O)=O

InChI

InChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N

InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C15H12I3NO4
Molecular Weight	650.9735
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6617571http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68014284

Liothyronine (CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system. Thyroid hormone drugs are indicated: as the replacement or supplemental therapy in patients with hypothyroidism of any etiology; as pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters; as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Thyroid hormone receptor alpha 14 Target ID: CHEMBL1860 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf	Agonist 2637	0.1 nM [Kd]
Thyroid hormone receptor beta-1 25 Target ID: CHEMBL1947 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf	Agonist 2637	0.1 nM [Kd]
Thyroid hormone receptor alpha 14 Target ID: CHEMBL1860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914	Agonist 2637	0.1 nM [Kd]
Thyroid hormone receptor beta-1 25 Target ID: CHEMBL1947 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12109914	Agonist 2637	0.1 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Hypothyroidism 10 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf	Primary	Approved 8307	CYTOMEL Approved Use Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date -4.3079041E11
Euthyroid goiters 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf	Primary	Approved 8307	CYTOMEL Approved Use Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date -4.3079041E11
Mild hyperthyroidism 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10379s47lbl.pdf	Diagnostic	Approved 8307	CYTOMEL Approved Use Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Launch Date -4.3079041E11
Hyperlipidemia 75 Sources: https://worldwide.espacenet.com/publicationDetails/claims?CC=US&NR=3917832A&KC=A&FT=D&ND=&date=19751104&DB=&locale=	Primary	Basic research	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
346 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
342 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
404 ng/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Analyte	Population
4370 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4740 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4926 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
12929 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13938 ng × h/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:	LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
22.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24977379	50 μg 1 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:		LIOTHYRONINE SODIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10794.4 ug 2 times / day multiple, oral Overdose Dose: 10794.4 ug, 2 times / day Route: oral Route: multiple Dose: 10794.4 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32158485 Page: p.2	unhealthy, 20 n = 1 Health Status: unhealthy Condition: Fatigue Age Group: 20 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/32158485 Page: p.2	Disc. AE: Anxiety, Palpitations... AEs leading to discontinuation/dose reduction: Anxiety (severe) Palpitations Agitation Shortness of breath Irritability Tachycardia Tremor Sources: https://pubmed.ncbi.nlm.nih.gov/32158485 Page: p.2
15000 ug 2 times / day multiple, oral Overdose Dose: 15000 ug, 2 times / day Route: oral Route: multiple Dose: 15000 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32158485 Page: p.2	unhealthy, 30 n = 1 Health Status: unhealthy Condition: Hypothyroidism Age Group: 30 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/32158485 Page: p.2	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea Vomiting Abdominal pain Headache (severe) Confusion Disorientation Diplopia Sources: https://pubmed.ncbi.nlm.nih.gov/32158485 Page: p.2
50 ug 2 times / day multiple, oral Highest studied dose Dose: 50 ug, 2 times / day Route: oral Route: multiple Dose: 50 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32120028 Page: p.3	unhealthy, 39 ± 6.2 n = 2 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/32120028 Page: p.3	DLT: Anxiety, Tachycardia... Dose limiting toxicities: Anxiety (50%) Tachycardia (50%) Loose stools (100%) Sources: https://pubmed.ncbi.nlm.nih.gov/32120028 Page: p.3
37.5 ug 2 times / day multiple, oral MTD Dose: 37.5 ug, 2 times / day Route: oral Route: multiple Dose: 37.5 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32120028 Page: p.3	unhealthy, 39 ± 6.2 n = 4 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 39 ± 6.2 Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/32120028 Page: p.3	Sources: https://pubmed.ncbi.nlm.nih.gov/32120028 Page: p.3

AEs

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-010973	http://www.3bsc.com/index/pro_info.php?id=33471
AA Blocks	AA0032E1	http://www.aablocks.com/goods/Goods/detail?id=AA0032E1
AEchem Scientific Corp., USA	AE044693	http://www.aechemsc.com/info_products/AE044693.php
AHH Chemical co.,ltd	MT-36644	http://www.ahhchemical.com/product/MT-36644.html
Aaron Chemicals	AR00335T	http://www.aaronchem.com/6893-02-3
AbMole Bioscience	M6079	http://www.abmole.com/products/triiodothyronine.html
Acros Organics	AC437260010	https://www.fishersci.com/shop/products/3-3-5-triiodo-l-thyronine-95-acros-organics/AC437260010
Alfa Aesar	H34068	https://www.alfa.com/en/catalog/H34068/
Alfa Chemistry	AP6893023-A	https://reagents.alfa-chemistry.com/product/3-3-5-triiodo-l-thyronine-t3-solution-cas-6893-02-3-15165.html
Alfa Chemistry	AP6893023-B	https://reagents.alfa-chemistry.com/product/liothyronine-cas-6893-02-3-15166.html
Alfa Chemistry	AP6893023-C	https://reagents.alfa-chemistry.com/product/liothyronine-cas-6893-02-3-15167.html
Alfa Chemistry	3130-96-9	https://www.alfa-chemistry.com/cas_3130-96-9.htm
Alsachim	3491	http://www.alsachim.com/product-C4781-glo.bal-view.html
Angene	AGN-PC-0WA1WH	http://www.angenechemical.com/productshow/AGN-PC-0WA1WH.html
Anward	ANW-60592	http://www.anward.com/pro_result/47043
Aurora Fine Chemicals LLC	A13.107.894	http://online.aurorafinechemicals.com/info?ID=A13.107.894
AvaChem Scientific	3931	http://www.avachem.com/productSearch.asp?3931
BLD Pharm	BD21401	http://www.bldpharm.com/products/6893-02-3.html
CSNpharm	CSN12771	https://www.csnpharm.com/products/triiodothyronine.html
Capot Chemical	20012	http://www.capotchem.com/en/20012.htm
Capot Chemical	PubChem20012	http://www.capotchem.com/en/20012.htm
Chem Scene	CS-4141	http://www.chemscene.com/6893-02-3.html
Chemspace	CSSB00000695812	https://chem-space.com/CSSB00000695812
Clearsynth	CS-O-31028	https://www.clearsynth.com/en/CSO31028.html
Debye Scientific	DB-021796	http://www.debyesci.com/DB-021796.html
Enamine	Z2216208625	https://www.enaminestore.com/catalog/Z2216208625
Glentham Life Sciences	GE2741	http://www.glentham.com/products/product/GE2741/
Hairui	HR132034	http://www.hairuichem.com/en/product/6893-02-3.html
Lab Network	LN00193201	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00193201
Matrix Scientific	94322	https://www.matrixscientific.com/094322.html
MedChem Express	HY-A0070A	https://www.medchemexpress.com/3,3_acute_,5-Triiodo-L-thyronine.html
MuseChem	R022695	https://www.musechem.com/product/R022695.html
OChem	6307	http://www.ocheminc.com/index.php?act=psearch&pid=893T023
Oakwood	102562	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=172240&ExtHyperLink=1
Sigma-Aldrich	564605_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/564605?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	T-074_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/t074?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	IRMM469_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/irmm469?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1504_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1504?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1368008_USP	https://www.sigmaaldrich.com/catalog/product/usp/1368008?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S525744	http://www.smolecule.com/products/s525744
Smolecule	S533244	http://www.smolecule.com/products/s533244
TCI (Tokyo Chemical Industry)	T0453	http://www.tcichemicals.com/eshop/en/us/commodity/T0453/index.html
THE BioTek	bt-267087	https://www.thebiotek.com/product/inhibitors/bt-267087
THE BioTek	bt-273145	https://www.thebiotek.com/product/inhibitors/bt-273145
Tocris	6666	https://www.tocris.com/products/t3_6666
VladaChem	VL261199-100MG	https://www.vladachem.com/product.php?products=6893-02-3
abcr GmbH	AB143218	http://www.abcr.com/shop/en/AB143218
abcr GmbH	AB426281	http://www.abcr.com/shop/en/AB426281
eNovation Chemicals	D489394	http://www.enovationchem.com/productDetails.asp?productID=D489394
eNovation Chemicals	D618757	https://www.enovationchem.com/ProductDetails.asp?ProductID=D618757

PubMed

Title	Date	PubMed
The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects.	1998 Nov	10197073
Arachidonic acid and PGE2 regulation of hepatic lipogenic gene expression.	1999 Jun	10357836
Interaction of amiodarone and triiodothyronine on the expression of beta-adrenoceptors in brown adipose tissue of rat.	1999 Mar	10217540
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells.	2000 Feb	10720163
Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor.	2000 Sep 22	11007966
Hypothalamus-hypophysis-thyroid axis, triiodothyronine and antithyroid antibodies in patients with primary and secondary Sjögren's syndrome.	2001	11254240
Effect of transient early hyperthyroidism on onset of puberty in Suffolk ram lambs.	2001 Apr	11277884
The pituitary-thyroid axis in healthy men living under subarctic climatological conditions.	2001 Apr	11250661
Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary.	2001 Apr	11250650
Habituation of thermal sensations, skin temperatures, and norepinephrine in men exposed to cold air.	2001 Apr	11247916
Nuclear cytoplasmic shuttling by thyroid hormone receptors. multiple protein interactions are required for nuclear retention.	2001 Apr 6	11152480
[Diabetes mellitus caused by pancreatitis in a bull].	2001 Feb	11234631
Differential in vitro suppressive effects of steroids on leukocyte phagocytosis in two teleosts, tilapia and common carp.	2001 Feb	11178882
Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators.	2001 Feb	11159836
Effect of hypothyroidism on pathways for iodothyronine and tryptophan uptake into rat adipocytes.	2001 Feb	11158928
Regulation of mucin gene expression in human tracheobronchial epithelial cells by thyroid hormone.	2001 Feb 1	11171071
Thyroid function after bone marrow transplantation: possible association between immune-mediated thyrotoxicosis and hypothyroidism.	2001 Feb 15	11233902
Thyroid hormone and the cardiovascular system.	2001 Feb 15	11172193
What is the optimal treatment for hypothyroidism?	2001 Feb 5	11247618
Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis.	2001 Jan	11280709
[Diagnosis of hyperthyroidism].	2001 Jan	11233497
Endogenous depression, thyroid function and acupuncture.	2001 Jan	11211567
Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.	2001 Jan	11167931
Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle.	2001 Jan	11133928
Subclinical thyrotoxicosis.	2001 Jan	11123391
Structure and expression of the transthyretin gene in the choroid plexus: a model for the study of the mechanism of evolution.	2001 Jan 1	11135445
An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo.	2001 Jun 8	11274156
The effects of triiodothyronine augmentation on antithrombin III levels in sepsis.	2001 Mar	11270884
Characterization of hepatic low-K(m) outer-ring deiodination in red drum (Sciaenops ocellatus).	2001 Mar	11250536
Perioperative considerations in a hypothyroid infant with hepatic haemangioma.	2001 Mar	11240884
Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism.	2001 Mar	11238502
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study.	2001 Mar	11238494
Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion.	2001 Mar	11238485
Homogeneous enzyme immunoassay for triiodothyronine in serum.	2001 Mar	11238313
Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression.	2001 Mar	11222747
Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression.	2001 Mar	11207942
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase.	2001 Mar 6	11258898
Slower skeletal muscle phenotypes are critical for constitutive expression of Hsp70 in overloaded rat plantaris muscle.	2006 Mar	16293703

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

The relative affinity of the rat synaptosomes for various T3 analogs was measured by incubating [3H]T3 with increasing amounts of T3, D-T3, T4, TRIAC and rT3, The results were expressed as the molar ratio of the concentrations of T3 or analog needed to decreaseby 50% the binding of [3H]T3.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:28:11 UTC 2022` Edited by `admin` on `Fri Dec 16 17:28:11 UTC 2022`
Record UNII	06LU7C9H1V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LIOTHYRONINE

Official Name

English

LIOTHYRONINE [MI]

Common Name

English

LEVOTHYROXINE SODIUM RELATED COMPOUND LIOTHYRONINE [USP IMPURITY]

Common Name

English

CYRONINE

Brand Name

English

T3

Common Name

English

NSC-80203

Code

English

LIOTHYRONINE [USP IMPURITY]

Common Name

English

3,5,3'-TRIIODOTHYRONINE, L-

Common Name

English

LEVOTHYROXINE SODIUM IMPURITY A [EP IMPURITY]

Common Name

English

Liothyronine [WHO-DD]

Common Name

English

LIOTHYRONINE [VANDF]

Common Name

English

O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-L-TYROSINE

Systematic Name

English

3,3',5-TRIIODO-L-THYRONINE

Systematic Name

English

L-TYROSINE, O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-

Systematic Name

English

3,5,3'-TRIIODOTHYRONINE

Systematic Name

English

RATHYRONINE, (S)-

Common Name

English

ALANINE, 3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)-, L-

Systematic Name

English

T-3

Common Name

English

TRIIODOTHYRONINE

Systematic Name

English

THYRONINE, 3,3',5-TRIIODO-, L-

Systematic Name

English

(2S)-2-AMINO-3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)PROPANOIC ACID

Systematic Name

English

liothyronine [INN]

Common Name

English

LIOTHYRONINE [HSDB]

Common Name

English

LIOTHYRONINE [USP-RS]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 862.1715